Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders
References (37)
- et al.
A new definition of Alzheimer's disease: a hippocampal dementia
Lancet
(1985) - et al.
Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex
Brain Res.
(1989) - et al.
Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition
Brain Res.
(1990) - et al.
Angiotensin converting enzyme activity is increase in temporal cortex from patients with Alzheimer's disease
Eur. J. Pharmacol.
(1991) - et al.
Identification and characterisation of angiotensin II receptor subtypes in human brain
Eur. J. Pharmacol.
(1993) - et al.
Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications
Frontiers Neuroendocrinol.
(1993) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
Two angiotensin II binding sites in rat brain revealed using [125I][Sar1,Ile8]angiotensin II and selective nonpeptide antagonist
Biochem. Biophys. Res. Commun.
(1990) - et al.
Effects of captopril and SQ 29,852 on anxiety-related behaviours in rodent and marmoset
Pharmacol. Biochem. Behav.
(1990) - et al.
Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain
Neurosci.
(1991)
Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes
J. Neurologi. Sci.
(1992)
Characterization of rat intestinal angiotensin II receptors
Eur. J. Pharmacol.
(1991)
Stimulating effect of angiotensin II on the spontaneous release of newly synthesized [3H]dopamine in rat striatal slices
Neurosci. Lett.
(1979)
Nonpeptide angiotensin II receptor antagonists
Trends Pharmacol. Sci.
(1991)
Angiotensin II receptor binding associated with nigro-striatal dopaminergic neurones in human basal ganglia
Ann. Neurol.
(1992)
Alterations in postmortem brain angiotensin-converting enzyme activity and some neuropeptides in Huntington's disease
Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas
J. Neurochem.
(1982)
Anxiolytic-like action of DuP753, a potent and selective non-peptide angiotensin II receptor antagonist
NeuroReport
(1990)
Cited by (98)
Therapeutic correlation of NOX4 and diabetes-mediated neurodegeneration
2023, Obesity MedicineACE2/angiotensin-(1–7)/mas receptor axis in the central nervous system
2023, Angiotensin: From the Kidney to CoronavirusSynaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer's disease
2018, Pharmacological ResearchIntegration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation
2018, European Journal of Medicinal ChemistryStructure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives
2018, Journal of Molecular Graphics and ModellingCitation Excerpt :The effects of AT1 antagonists are not limited to cardiovascular diseases. It is reported that AT1 receptor blockers may be used as potential anti-cancer agents − due to the inhibition of cell proliferation stimulated by A-II − and also can be used against Alzheimer’s disease [7,8]. Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such diseases.
Copyright © 1996 Published by Elsevier B.V.